Elevance Health ELV · USD
Health Care · Health Care Providers & Services · US listing · 🇺🇸 United States
S&P 500
418.25
-1.73%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Elevance Health annual report
Filed with the US Securities and Exchange Commission
The latest annual report covers the year to 31 Dec 2025, filed on 6 Feb 2026.
Read the 10-K on SEC.gov ↗Five-year highlights
In USD.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $199.13bn | $176.81bn | $171.34bn | $156.59bn | $138.64bn |
| Operating income | $8.11bn | $8.89bn | $8.74bn | $8.45bn | $8.95bn |
| Net income | $5.66bn | $5.98bn | $5.99bn | $5.89bn | $6.10bn |
| Free cash flow | $3.17bn | $4.55bn | $6.76bn | $7.25bn | $7.28bn |
| Total assets | $121.49bn | $116.89bn | $108.93bn | $102.75bn | $97.46bn |
| Shareholders' equity | $43.88bn | $41.31bn | $39.31bn | $36.24bn | $36.06bn |
Revenue by business
Year to 31 Dec 2024
- Reportable Segments $177.01bn · 100.0%
From the 2025 annual report
As filed, for the year to Dec. 31, 2025. A later report may be linked above: this is the newest our data supplier has processed.
- Document
- 10-K
- Registrant
- ELEVANCE HEALTH, INC.
- Fiscal year end
- Dec. 31, 2025
- Listed on
- NYSE
- Filer category
- Large Accelerated Filer
- Auditor
- Ernst & Young LLP
- Auditor location
- Indianapolis, Indiana
Income statement USD ($) $ in Millions
| Dec. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2023 | |
|---|---|---|---|
| Premiums | 164,639 | 144,166 | 142,854 |
| Total operating revenue | 197,584 | 175,204 | 170,209 |
| Net investment income | 2,194 | 2,051 | 1,825 |
| Net losses on financial instruments | -653 | -445 | -694 |
| Gain on sale of business | 0 | 201 | 0 |
| Total revenues | 199,125 | 177,011 | 171,340 |
| Benefit expense | 148,223 | 127,567 | 124,330 |
| Cost of products sold | 21,178 | 19,750 | 17,293 |
| Operating expense | 20,984 | 20,025 | 20,087 |
| Interest expense | 1,402 | 1,185 | 1,030 |
| Amortization of other intangible assets | 628 | 580 | 885 |
| Total expenses | 192,415 | 169,107 | 163,625 |
| Income before income tax expense | 6,710 | 7,904 | 7,715 |
| Income tax expense | 1,049 | 1,933 | 1,724 |
| Net income | 5,661 | 5,971 | 5,991 |
| Net loss (gain) attributable to noncontrolling interests | 1 | 9 | -4 |
| Shareholders’ net income | 5,662 | 5,980 | 5,987 |
| Basic (in dollars per share) | 25.28 | 25.81 | 25.38 |
| Diluted (in dollars per share) | 25.21 | 25.68 | 25.22 |
| Product and service revenue | 24,470 | 22,630 | 19,452 |
| Product and service revenue | 8,475 | 8,408 | 7,903 |
Balance sheet USD ($) $ in Millions
| Cash and cash equivalents | 9,491 | 8,288 |
|---|---|---|
| Fixed maturity securities (amortized cost of $25,773 and $25,879; allowance for credit losses of $21 and $6) | 25,884 | 25,201 |
| Equity securities | 740 | 1,192 |
| Premium receivables | 10,073 | 8,011 |
| Self-funded receivables | 5,162 | 5,044 |
| Other receivables | 6,307 | 6,016 |
| Other current assets | 5,344 | 4,700 |
| Assets held for sale | 0 | 490 |
| Total current assets | 63,001 | 58,942 |
| Fixed maturity securities (amortized cost of $1,116 and $1,049; allowance for credit losses of $0 and $0) | 1,121 | 1,035 |
| Other invested assets | 10,839 | 9,749 |
| Property and equipment, net | 4,679 | 4,652 |
| Goodwill | 28,344 | 28,277 |
| Other intangible assets | 11,200 | 12,094 |
| Other noncurrent assets | 2,310 | 2,140 |
| Total assets | 121,494 | 116,889 |
| Medical claims payable | 17,084 | 15,746 |
| Other policyholder liabilities | 3,632 | 4,204 |
| Unearned income | 1,493 | 1,508 |
| Accounts payable and accrued expenses | 7,322 | 6,927 |
| Short-term borrowings | 150 | 365 |
| Current portion of long-term debt | 1,099 | 1,649 |
| Other current liabilities | 10,255 | 10,029 |
| Liabilities held for sale | 0 | 153 |
| Total current liabilities | 41,035 | 40,581 |
| Long-term debt, less current portion | 30,797 | 29,218 |
| Reserves for future policy benefits | 145 | 190 |
| Deferred tax liabilities, net | 2,110 | 2,148 |
| Other noncurrent liabilities | 3,381 | 3,326 |
| Total liabilities | 77,468 | 75,463 |
| Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none | 0 | 0 |
| Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 220,723,898 and 227,479,695 | 2 | 2 |
| Additional paid-in capital | 8,938 | 8,911 |
| Retained earnings | 35,393 | 33,549 |
| Accumulated other comprehensive loss | -451 | -1,147 |
| Total shareholders’ equity | 43,882 | 41,315 |
| Noncontrolling interests | 144 | 111 |
| Total equity | 44,026 | 41,426 |
| Total liabilities and equity | 121,494 | 116,889 |
Cash flow statement
| Dec. 31, 2025 USD ($) | Dec. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | |
|---|---|---|---|
| Net income | 5,661 | 5,971 | 5,991 |
| Net losses on financial instruments | 653 | 445 | 694 |
| Gain on sale of business | 0 | -201 | 0 |
| Equity in net (earnings) losses of other invested assets | -398 | -1 | 33 |
| Depreciation and amortization | 1,546 | 1,393 | 1,745 |
| Deferred income taxes | -279 | -374 | -602 |
| Impairment of property, equipment and right-of-use assets | 108 | 103 | 446 |
| Share-based compensation | 276 | 191 | 289 |
| Receivables, net | -2,526 | -683 | -1,762 |
| Other invested assets | 0 | -78 | -79 |
| Other assets | 57 | 824 | -675 |
| Policy liabilities | 228 | -1,840 | 147 |
| Unearned income | -15 | -113 | 290 |
| Accounts payable and other liabilities | -720 | -272 | 1,640 |
| Income taxes | -297 | 404 | -103 |
| Other, net | -4 | 39 | 7 |
| Net cash provided by operating activities | 4,290 | 5,808 | 8,061 |
| Purchases of investments | -15,026 | -17,986 | -16,236 |
| Proceeds from sale of investments | 13,324 | 16,547 | 10,596 |
| Maturities, calls and redemptions from investments | 1,771 | 2,025 | 2,940 |
| Changes in securities lending collateral | -385 | 73 | 78 |
| Purchases of subsidiaries, net of cash acquired | 88 | -4,809 | -1,552 |
| Proceeds from sales of subsidiaries, net of cash sold | 0 | 363 | 0 |
| Purchases of property and equipment | -1,116 | -1,256 | -1,296 |
| Other, net | 0 | -124 | -102 |
| Net cash used in investing activities | -1,344 | -5,167 | -5,572 |
| Proceeds from long-term borrowings, net issuance costs | 2,991 | 7,710 | 2,574 |
| Repayments of long-term borrowings | -2,147 | -1,650 | -1,909 |
| Proceeds from short-term borrowings | 1,505 | 275 | 225 |
| Repayments of short-term borrowings | -1,720 | -135 | -265 |
| Changes in securities lending payable | 386 | -75 | -77 |
| Changes in bank overdrafts | 1,312 | -638 | 114 |
| Repurchase and retirement of common stock | -2,605 | -2,900 | -2,676 |
| Cash dividends | -1,529 | -1,508 | -1,395 |
| Proceeds from issuance of common stock under employee stock plans | 79 | 221 | 152 |
| Taxes paid through withholding of common stock under employee stock plans | -32 | -109 | -99 |
| Other, net | 22 | 2 | 7 |
| Net cash provided by (used in) financing activities | -1,738 | 1,193 | -3,349 |
| Effect of foreign exchange rates on cash and cash equivalents | -5 | -6 | -1 |
| Change in cash and cash equivalents | 1,203 | 1,828 | -861 |
| Cash and cash equivalents at beginning of year | 8,288 | 6,526 | 7,387 |
| Less cash and cash equivalents included in assets held for sale at end of year | 0 | -66 | 0 |
| Cash and cash equivalents at end of year | 9,491 | 8,288 | 6,526 |
Note: Segment Information
Segment InformationWe report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. An immaterial amount of our total consolidated revenues is derived from activities outside of the U.S. and Puerto Rico.Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid and FEP® members. The Health Benefits segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as stop loss, dental, vision and supplemental health insurance benefits.Our CarelonRx segment includes our pharmacy services business. CarelonRx markets and offers pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a comprehensive pharmacy services portfolio, which includes all core pharmacy services, such as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database and member services, as well as infusion services and injectable therapies.Our Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services and capabilities to internal and external customers through our Carelon Health and Carelon Insights businesses. Carelon promotes affordability by managing complex areas of the healthcare system, leveraging data and insights to ensure members receive safe, appropriate, high-quality care and providers are reimbursed accurately and timely. Our approach to cost management relies on capabilities including provider enablement, value-based networks, member engagement, and utilization management. Our care delivery services primarily target serving chronic and complex populations by providing personalized care in the home and virtually. As a part of Carelon Health, we completed our acquisition of CareBridge at the end of 2024, which provides virtual care to complex Medicaid and Medicare patients and supports plans in managing home and community-based services.
Note: Commitments and Contingencies
Commitments and ContingenciesLitigation and Regulatory Proceedings We are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below.Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or probable or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible or probable loss or range of losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. With respect to the cases described below, we contest liability and/or the amount of damages in each matter, and we believe we have meritorious defenses. We do not believe the outcome of any known pending or threatened legal actions or proceedings will, in the aggregate, have a material impact on our financial position. However, unanticipated outcomes do sometimes occur, which could result in liabilities in excess of our accruals and could have a material adverse effect on our consolidated financial position or results of operations.In addition to the lawsuits described below, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings (“government actions”).
Note: Debt
DebtShort-term BorrowingsWe are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At December 31, 2025 and 2024, $150 and $365, respectively, were outstanding under our short-term FHLB borrowings. Outstanding short-term FHLB borrowings at December 31, 2025 had fixed interest rates of 3.78%.We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. On September 5, 2025, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the maturity date of the 5-Year Facility from April 2027 to September 2030 and increase the amount of credit available under the 5-Year Facility from $4,000 to $5,000. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of December 31, 2025, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 42.1%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of December 31, 2025, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility at any time during the years ended December 31, 2025 or 2024.We have an authorized commercial paper program of up to $5,000, the proceeds of which may be used for general corporate purposes. In October 2025, we increased the amount available under the commercial paper program from $4,000 to $5,000. There were no amounts outstanding under our commercial paper program at December 31, 2025 or 2024.Long-term DebtThe carrying value of our long-term debt at December 31, 2025 and 2024 consists of the following:20252024Senior unsecured notes:2.375%, due 2025— 1,250 5.350%, due 2025— 399 1.500%, due 2026750 749 4.500%, due 2026349 349 4.900%, due 2026— 499 3.650%, due 20271,597 1,596 4.000%, due 2028747 — 4.101%, due 20281,244 1,238 2.875%, due 2029823 822 5.
Note: Income Taxes
Income TaxesThe components of deferred income taxes at December 31, 2025 and 2024 are as follows:20252024Deferred income tax assets:Accrued expenses$652 $826 Bad debt reserves465 434 Insurance reserves122 192 Lease liabilities137 170 Retirement liabilities107 126 Deferred compensation42 45 Federal and state carryforwards617 428 Foreign (including Puerto Rico) carryforwards236 139 Other53 51 Subtotal2,431 2,411 Less: valuation allowance(311)(294)Total deferred income tax assets2,120 2,117 Deferred income tax liabilities:U.S. federal and state intangible assets2,447 2,584 Foreign (including Puerto Rico) intangible assets125 194 Capitalized software439 513 Depreciation and amortization20 38 Investment basis276 11 Retirement assets295 330 Lease right-of-use assets89 114 Prepaid expenses240 275 Total deferred income tax liabilities3,931 4,059 Net deferred income tax liabilities$1,811 $1,942 Deferred tax balances are classified by deferred tax assets and deferred tax liabilities by taxing jurisdiction in the financial statements. We recognized $298 and $206 of deferred tax asset under the caption “Other noncurrent assets” at December 31, 2025 and 2024, respectively. We recognized $2,110 and $2,148 of deferred tax liability under the caption “Deferred tax liabilities, net” at December 31, 2025 and 2024, respectively.As of December 31, 2025, we have established U.S. deferred taxes for undistributed earnings from certain non-U.S. subsidiaries, which are included in the Investment basis component above, consistent with prior years.Significant components of income before income tax expense for the years ended December 31, 2025, 2024 and 2023 consist of the following:202520242023Domestic U.S.6,322 7,629 7,580 Foreign (including Puerto Rico)388 275 135 Income before income tax expense$6,710 $7,904 $7,715 Income before income taxes, as shown above, is based on the location of the entity to which such earnings are attributable. Where an entity’s earnings are subject to taxation, however, may not correlate solely to where an entity is located. Thus, the income tax provision shown below as federal or foreign may not correspond to the earnings shown above.
Note: Leases
LeasesWe lease office space and certain computer and related equipment using noncancelable operating leases. Our leases have remaining lease terms of 1 year to 11 years.The information related to our leases is as follows:Balance Sheet LocationDecember 31, 2025December 31, 2024Operating LeasesROU assetsOther noncurrent assets$452 $567 Lease liabilities, currentOther current liabilities131 153 Lease liabilities, noncurrentOther noncurrent liabilities$529 $658 Years Ended December 31202520242023Lease ExpenseOperating lease expense$116$147$155Short-term and variable lease expense424743Sublease income(5)(6)(5)Total lease expense$153$188$193 During the years ended December 31, 2025, 2024 and 2023, we reduced our office space footprint and concurrently performed an interim impairment test for related ROU assets. We recorded impairment charges of $7, $17 and $23, respectively, for impairment and abandonment of ROU assets which are included in the operating lease expense shown above.Years Ended December 3120252024Other informationOperating cash paid for amounts included in the measurement of lease liabilities, operating leases$176$202ROU assets obtained in exchange for new lease liabilities, operating leases3363ROU assets derecognized (terminations/modifications)$(75)$(19)Weighted average remaining lease term in years, operating leases66Weighted average discount rate, operating leases4.05 %3.
Note: Business Acquisitions
Business AcquisitionsCompleted AcquisitionsOn December 31, 2024, we completed our acquisition of Centers Plan for Healthy Living LLC and Centers for Specialty Care Group IPA, LLC (“Centers”). Centers is a managed long-term care plan that serves New York state Medicaid and dual-eligible Medicaid/Medicare members, enabling adults with long-term care needs and disabilities to live safely and independently in their own home. This acquisition aligns with our strategic plan to grow the Health Benefits segment and leverage industry-leading expertise while serving Medicaid and dual-eligible populations. As of December 31, 2025, the purchase price was allocated to the tangible and intangible net assets acquired based on management's initial estimates of their fair values, of which $211 has been allocated to finite-lived intangible assets, $690 to indefinite-lived intangible assets and $202 to goodwill. The majority of the goodwill is not deductible for income tax purposes. As of December 31, 2025, the initial accounting for the acquisition was finalized. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.On December 10, 2024, we completed our acquisition of RSV QOZB LTSS, Inc. and certain affiliated entities (“CareBridge”), a value-based healthcare company that manages home and community-based services for Medicaid and dual-eligible members receiving long-term services and support. This acquisition aligns with Carelon Services’ care at home strategy, and our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. As of December 31, 2025, the purchase price was allocated to the tangible and intangible net assets acquired based on management's initial estimates of their fair values, of which $305 has been allocated to finite-lived intangible assets and $1,827 to goodwill. The majority of the goodwill is not deductible for income tax purposes. As of December 31, 2025, the initial accounting for the acquisition was finalized. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.During the year ended December 31, 2025, in total, we completed business combinations for total cash consideration of approximately $414.
Note: Cybersecurity Risk Management a
Our comprehensive cybersecurity and risk management programs are part of our continuously evolving enterprise-wide risk management practices. Aligned and measured against the National Institute of Standards and Technology (NIST) Cybersecurity Framework, recognized best practices and standards for cybersecurity and information technology, industry and government standards and other guidelines, our cybersecurity and risk management programs utilize policies, processes, and technologies to identify, assess, manage and mitigate cybersecurity risks and threats we face. We also conduct periodic reviews and updates to uphold our security standards, including implementation of tabletop crises exercises. Our management implements ongoing and annual risk assessment processes to identify and manage risks that could affect our ability to safeguard sensitive data or provide reliable transaction processing and to minimize financial risk exposure. These risks include, but are not limited to, legal and regulatory compliance; third-party management, including risks from business partners and software providers; mergers and acquisitions; system availability and disruption of business operations; data use and security; vulnerability and configuration management; fraud and extortion; and reputational risk. The steps we take to reduce vulnerability to cyber-attacks and to mitigate and remediate the impact of cybersecurity incidents in a timely and coordinated manner include, but are not limited to: establishing information security policies and standards, implementing information protection processes, tools and technologies, monitoring information technology systems for cybersecurity threats, coordinating internal reporting, assessing cybersecurity risk profiles of key third-parties, implementing cybersecurity training and collaborating with public and private organizations on cyber threat information and best practices.In addition to our internal Information Security teams, we utilize trusted third-party auditors and recognized cybersecurity consultants and certified assessors, to assess our cybersecurity risks, related controls, and alignment to relevant regulatory and legal requirements. A third-party evaluates our information security policies, standards and control environment at least annually. Assessments and testing protocols are performed by third parties against industry best practices and widely recognized security frameworks.
Note: Fair Value
Fair ValueAssets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:Level Input: Input Definition:Level I Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.Level II Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.Level III Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in the consolidated balance sheets:Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at par value with specified yield rates. Due to the short-term nature of the funds, we designate all cash equivalents as Level I.Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities, United States Government securities, foreign government securities, and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable.
Long notes are shortened. The full text is in the filing.
Filings
Newest first, from SEC EDGAR
- Quarterly report (10-Q) ↗ Filed 21 Oct 2026
- Current report (8-K) ↗ Filed 21 Oct 2026
- Current report (8-K) ↗ Filed 10 Sept 2026
- Quarterly report (10-Q) ↗ Filed 15 Jul 2026
- Current report (8-K) ↗ Filed 15 Jul 2026
- Current report (8-K) ↗ Filed 10 Jun 2026
- Current report (8-K) ↗ Filed 13 May 2026
- Quarterly report (10-Q) ↗ Filed 22 Apr 2026
- Current report (8-K) ↗ Filed 22 Apr 2026
- Proxy statement (DEF 14A) ↗ Filed 27 Mar 2026
- Quarterly report (10-Q) ↗ Filed 21 Oct 2025
- Proxy statement (DEF 14A) ↗ Filed 28 Mar 2025
- Annual report (10-K) ↗ Filed 20 Feb 2025
- Annual report (10-K) ↗ Filed 21 Feb 2024
- Annual report (10-K) ↗ Filed 15 Feb 2023
- Annual report (10-K) ↗ Filed 16 Feb 2022
Sources and methodology
- Data on this tab
- SEC EDGAR and our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.